Naltrexone And Buprenorphine Market (2025 - 2033)

Naltrexone And Buprenorphine Market Summary

The global naltrexone and buprenorphine market size was estimated at USD 4.17 billion in 2024 and is projected to reach USD 9.80 billion by 2033, growing at a CAGR of 9.25% from 2025 to 2033. The market is expected to grow due to the increasing prevalence of substance use disorders and greater awareness of opioid use disorder treatments. Government initiatives are further increasing access to advanced addiction care solutions.

WHO Updates Opioid Treatment Guidelines

In February 2025, The World Health Organization (WHO) updated its guidelines on opioid dependence treatment and overdose prevention to expand access to effective interventions. The revised guidelines emphasized the importance of using opioid agonist maintenance treatment (OAMT) with methadone or buprenorphine as the most effective therapy for opioid dependence. WHO also recommended making naloxone more widely available to prevent overdose-related deaths, especially in community settings. The new guidance called for reducing regulatory barriers and increasing investment in harm-reduction services. Additionally, the update urged healthcare providers to deliver evidence-based, person-centered, and non-discriminatory care. These recommendations were aimed at supporting countries in addressing rising opioid-related health challenges and enhancing public health outcomes globally.

Telemedicine Expansion Approved for Buprenorphine Treatment

In January 2025, the Federal Register published a rule titled “Expansion of Buprenorphine Treatment via Telemedicine Encounter,” which allowed authorized practitioners to initiate buprenorphine treatment for opioid use disorder (OUD) through telemedicine without requiring an in-person evaluation. The rule was issued to enhance access to care, particularly in underserved and rural areas, by leveraging telehealth platforms. It outlined that practitioners must be registered with the Drug Enforcement Administration (DEA) and comply with all applicable federal and state regulations. The rule also specified that adequate patient assessment, documentation, and follow-up care were necessary to ensure safe and effective treatment. This policy change aimed to support continuity of care, reduce treatment delays, and address the growing opioid crisis. The expansion marked a significant shift in how medication-assisted treatment could be delivered across the U.S.

Strategic Phase 3 Advancements in Long-Acting Therapies for Opioid Use Disorder

The current Phase 3 pipeline for opioid use disorder (OUD) demonstrates strong strategic investment by Braeburn Pharmaceuticals, Alkermes, Inc., and Indivior Inc., with a clear focus on long-acting buprenorphine and extended-release naltrexone therapies. These trials address key clinical challenges such as improving treatment adherence, enhancing safety during transitions, and reducing relapse risk. Alkermes is exploring the combined use of buprenorphine and naltrexone to support patients switching to Vivitrol. Indivior is advancing depot buprenorphine formulations focusing on safety and long-term use. Braeburn’s trial on CAM2038 reflects the broader push for outpatient-appropriate, sustained-release options. Collectively, these late-stage programs indicate a shift toward long-acting pharmacologic solutions that align with payer demands and public health goals for more effective, low-diversion-risk treatments in OUD care.

Clinical Trials Targeting Opioid Use Disorder (OUD)

The retail pharmacies segment is expected to experience significant growth over the forecast period. These pharmacies play a vital role in opioid use disorder (OUD) treatment by improving access to medications such as buprenorphine and naltrexone. Their convenient locations allow patients to fill prescriptions and receive counseling that supports treatment adherence easily. Retail pharmacies also contribute to public health efforts aimed at addressing the opioid crisis. Their strong community presence and accessibility make them essential in expanding treatment reach and improving outcomes for individuals with OUD.

Regional Insights

North America naltrexone and buprenorphine market held the largest revenue share of 39.4% in 2024. The market is expected to witness steady growth over the forecast period, primarily fueled by the rising incidence of substance use disorders, particularly Opioid Use Disorder (OUD). Contributing factors include improved awareness of treatment options, broader insurance coverage, and enhanced patient affordability. Increased rates of opioid prescriptions, persistent pain conditions, excessive alcohol intake, and limited access to appropriate care are key contributors to the OUD burden. These elements are collectively driving demand for effective pharmacological therapies. As treatment adoption expands, the market is likely to grow consistently.

U.S. Naltrexone And Buprenorphine Market Trends

The U.S. naltrexone and buprenorphine market holds the largest share of the North American market, supported by growing awareness among healthcare professionals and an increasing number of opioid use disorder (OUD) cases. Enhanced understanding of available treatment options has contributed to the broader adoption of these medications. Data from the CDC indicates that over 131 million opioid-related prescriptions were filled in the U.S. in 2022. Additionally, approximately 145,000 individuals received a new diagnosis of OUD during the same year. These trends underscore the urgent need for effective treatment solutions and continue to drive market expansion.

Europe Naltrexone And Buprenorphine Market Trends

Europe naltrexone and buprenorphine market demonstrated steady growth in 2024, supported by the rising burden of substance use disorders and expanding clinical treatment infrastructure. Hospitals and addiction care networks across the region use medication-assisted therapies to manage OUD and AUD. Availability of cost-effective generic formulations has enhanced access in both the public and private sectors. The growing emphasis on relapse prevention and long-term recovery is influencing treatment choices. Partnerships between healthcare systems and academic institutions are encouraging evidence-based therapeutic approaches. These trends collectively strengthen the regional market outlook.

The UK naltrexone and buprenorphine market is experiencing notable growth, driven by the rising incidence of substance use disorders and the expansion of structured treatment programs. In 2023, more than half of the individuals with Opioid Use Disorder (OUD) in England, the UK’s largest constituent nation, were actively receiving treatment. Most patients were administered Medications for Opioid Use Disorder (MOUD), including buprenorphine, methadone, or naltrexone. This indicates strong clinical adoption and prioritization of pharmacological therapy in managing addiction. By comparison, treatment rates in the U.S. remain lower, with under 30% of individuals with OUD receiving care. This disparity highlights the UK’s more integrated approach to addressing opioid dependency.

Naltrexone and buprenorphine market in Germany advanced steadily in 2024 due to consistent clinical use of these therapies in addiction care settings. Structured treatment models and high therapeutic adherence support market growth. Buprenorphine is frequently prescribed for opioid withdrawal and maintenance due to its efficacy and safety. Naltrexone usage is increasing, especially for managing alcohol dependence in outpatient programs. Healthcare providers prioritize evidence-based treatment, which has helped integrate these medications into standard protocols. This contributes to Germany’s continued growth within the European market.

France naltrexone and buprenorphine market maintained stable growth in 2024, supported by expanding treatment access and rising alcohol-related health concerns. Clinicians routinely prescribe buprenorphine for opioid addiction management across both inpatient and outpatient settings. The adoption of naltrexone is increasing among adults with alcohol use disorder. New formulations and flexible dosing options have improved treatment personalization. Medical professionals are focusing on patient-centered approaches to minimize relapse. These developments are supporting long-term market expansion in France.

Asia Pacific Naltrexone And Buprenorphine Market Trends

The Asia Pacific naltrexone and buprenorphine market is expected to register the fastest CAGR of 9.82% over the forecast period, driven by rising treatment demand and expanding healthcare access. Urbanization and improved diagnostic capabilities are increasing the identification of OUD and AUD cases. Pharmaceutical companies are scaling up regional manufacturing and distribution to meet demand. Medication-assisted therapy is being integrated into treatment frameworks across emerging economies. Awareness campaigns have improved the understanding of pharmacological options among healthcare providers. These shifts are accelerating adoption and fueling strong regional growth.

Japan naltrexone and buprenorphine market showed a gradual improvement in 2024, influenced by shifting perspectives on substance use as a medical condition. Medical professionals are incorporating pharmacological therapy into structured recovery programs. Buprenorphine is being used in specialty addiction clinics for long-term opioid maintenance. Naltrexone use is also increasing in the management of alcohol use disorder in adult populations. Providers are promoting adherence through careful monitoring and follow-up care. These factors support moderate but steady market growth in Japan.

China naltrexone and buprenorphine market expanded rapidly in 2024, supported by a rising awareness of OUD treatment and increased alcohol-related health interventions. Hospitals and public health institutions are adopting medication-assisted therapy for both conditions. Injectable buprenorphine and oral naltrexone are being introduced across urban and semi-urban centers. Domestic manufacturers are investing in scaling up access and lowering treatment costs. Clinical training and pilot programs have increased professional familiarity with these therapies. This evolving treatment landscape supports sustained market momentum in China.

Latin America Naltrexone And Buprenorphine Market Trends

Latin America naltrexone and buprenorphine market progressed in 2024 with growing substance use concerns and the expansion of addiction care services. Healthcare systems are gradually incorporating pharmacological treatment into outpatient and residential programs. Brazil, Argentina, and Mexico remain major contributors due to rising demand and improved access. Clinicians are increasing reliance on buprenorphine for opioid dependence and on naltrexone for alcohol abuse. Efforts to reduce stigma and increase provider education are improving treatment adherence. These drivers are building a foundation for continued regional market growth.

Brazil naltrexone and buprenorphine market grew steadily in 2024 due to a greater focus on addiction treatment infrastructure and rising patient engagement. Buprenorphine is widely used in urban clinics for opioid dependence management. Naltrexone is gaining attention in primary care settings for addressing alcohol-related disorders. Availability of affordable formulations has improved patient access. Health professionals are emphasizing treatment continuity and follow-up, which boosts adherence. These elements are reinforcing market growth across Brazil.

Middle East & Africa Naltrexone And Buprenorphine Market Trends

The Middle East & Africa naltrexone and buprenorphine market experienced rising demand in 2024 due to growing treatment needs and improved clinical infrastructure. Providers in key markets are incorporating long-acting formulations into structured recovery plans. Buprenorphine’s favorable safety profile is encouraging its use across specialized clinics. Naltrexone is being prescribed in urban centers for managing alcohol dependence. Educational initiatives are helping reduce treatment resistance and increase acceptance. These changes are fostering market development across multiple MEA countries.

Saudi Arabia naltrexone and buprenorphine market expanded in 2024 with increased clinical adoption of evidence-based addiction therapies. Treatment centers are integrating buprenorphine into care protocols for opioid withdrawal and maintenance. Naltrexone is gaining use for managing alcohol-related conditions among adult populations. Clinical professionals are receiving training on medication-assisted therapy to enhance treatment precision. Local distribution partnerships are helping improve availability and consistency in supply. These trends are supporting stable growth in Saudi Arabia’s addiction treatment market.

Key Naltrexone And BuprenorphineCompany Insights

Key players in the naltrexone and buprenorphine market include Alkermes plc, Indivior PLC, Orexo AB, and Camurus, which significantly advance therapeutic innovations. These companies lead the market by developing new treatment options and advanced delivery technologies. Emerging participants such as BioCorRx, Inc., Braeburn, Inc., and Delpor, Inc. are gaining traction by focusing on innovative product pipelines and expanding their presence in underserved areas. Their strategies often involve securing financial backing from healthcare institutions and launching differentiated therapies. This mix of established leaders and agile entrants shapes a dynamic and evolving competitive landscape.

Recent Developments

• In June 2025, Indivior PLC shared data showing that 300 mg SUBLOCADE improved outcomes in OUD patients with heavy fentanyl use. They also highlighted treatment barriers among American Indian/Alaska Native populations facing higher overdose death rates. The findings support tailored strategies to improve OUD care.

• In March 2025, Collegium Pharmaceutical Inc. revealed plans to showcase four real-world data posters from its distinct pain management portfolio at PainConnect 2025, the annual American Academy of Pain Medicine meeting.

• In February 2025, Indivior PLC received FDA approval for label updates to SUBLOCADE based on a Phase 3 study showing sustained clinical response and treatment retention over 12 months. The updated label includes revised pharmacology data on buprenorphine levels and drug interactions.

• In May 2024, Novo Nordisk purchased Alkermes plc’s development and manufacturing site in Athlone, Ireland, for USD 91 million. Meanwhile, Alkermes will maintain operations at its manufacturing facility in Wilmington, Ohio, where it will continue producing its proprietary commercial therapies ARISTADA, VIVITROL, ARISTADA INITIO, and LYBALVI.

• In October 2023, Indivior PLC acquired exclusive worldwide rights to develop, manufacture, and commercialize a series of long-acting injectable therapies from Alar Pharmaceuticals Inc. The agreement covers multiple formulations designed for extended buprenorphine prodrug release, including the prominent injectable candidate ALA-1000.

• In September 2023, Camurus AB launched Brixadi, a weekly and monthly buprenorphine-based medication approved for managing mild to intense opioid use disorder (OUD). This treatment is suitable for individuals already on daily buprenorphine therapy or those initiating care with a single dose of transmucosal buprenorphine.

Naltrexone And Buprenorphine Market